Partner Therapeutics (PTx) currently supports 6 clinical trials across 5 therapeutic areas to address gaps in knowledge and unmet medical needs and ultimately improve patient care.

PTx is committed to supporting investigator-sponsored research (clinical and non-clinical) that enhances the scientific and medical understanding of our products and therapeutic areas, and, ultimately, improves patient care. Please contact partnertx@medcomminc.com with proposals.

Thank you to the clinicians and patients involved in clinical trials. We could not do this without you!

Current Sargramostim Clinical Trials (Company-sponsored and Investigator-sponsored)

Cancer

Melanoma

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV  Melanoma

Hematologic Malignancies

Phase II Trial Evaluating the Efficacy and Safety of Sargramostim Post-Infusion of T-Replete HLA Mismatched Peripheral Blood Haploidentical Hematopoietic Stem Cells and With Post Transplant  Cyclophosphamide

Breast Cancer

Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)

Critical Care

Sepsis Trials in Critical Care (SepTIC)

GM-CSF for Reversal of Immunoparalysis in Pediatric Sepsis-induced MODS (GRACE-2)

Inhaled sargramostim in groups of healthy and intensive care unit participants to study alveolar macrophage function – a clinical trial (INSIGHT-AM)

Vascular Disease

Peripheral Arterial Disease

Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease (GPAD-3)

Note: Not all clinical trials including Sargramostim are listed.